COLUMBIA, S.C. — CurTec USA (CurTec), a high-performance packaging manufacturer, today announced it is expanding its operations in Oconee County. The company’s $10 million investment will create 10 new jobs. 

Founded in 1991, CurTec produces plastic drums, pails and jars to safely handle and contain critical materials in the life sciences and fine chemicals industries. With production operations in the U.S. and Netherlands and a commercial presence in Asia, Europe and North America, the company has an international footprint including its Oconee County facility.

CurTec, located at 365 Oconee Business Parkway in Westminster, will expand its existing warehouse and production lines to increase its capacity to manufacture and store drums and pails for pharmaceutical markets.

Operations are expected to be online in the summer of 2027. Individuals interested in joining the CurTec team should visit the company’s careers page.

“When we opened our Westminster facility in 2023, our goal was to bring production closer to our North American customers and build a platform for long-term growth. This expansion is the next step. By increasing local production, capacity and inventory, we can strengthen supply reliability, broaden the range we manufacture in the United States and continue growing our team and operations in South Carolina.”
-CurTec CEO Bart van Berkel

“CurTec’s decision to expand in Oconee County further strengthens its commitment to South Carolina. We are proud to see the company continue investing in our state, creating 10 new jobs and strengthening our manufacturing workforce.”
-Gov. Henry McMaster

“Congratulations to CurTec on its expansion in the Upstate. With South Carolina’s continued growth in the life sciences industry, we are excited to see this investment come to fruition.”
-Secretary of Commerce Harry M. Lightsey III

“We are excited to witness CurTec’s continued growth in Oconee County. They have learned what we know – our workers and our business climate make Oconee a great place to operate a business and raise a family. CurTec’s expansion is another win for our area and sends a strong signal to other companies looking for a great place to locate.”
-Senate President Thomas C. Alexander

“It is another ‘Top Shelf for Business’ day in Oconee County with CurTec’s decision to invest and create additional jobs at their Westminster manufacturing facility. Just three years after opening the facility, the project reflects CurTec’s confidence in our excellent workforce and strong business climate. CurTec is an outstanding company and we greatly value our partnership with them. Oconee County is pleased to support this expansion and looks forward to seeing the company continue to grow in our community.
-Oconee Economic Alliance President and CEO Jamie Gilbert

COLUMBIA, S.C. — Obatala Sciences (Obatala), a biotechnology company, today announced it selects Charleston County for its first East Coast operation. The company’s $656,000 investment will create 46 new jobs and training opportunities in biotechnology and related fields.

Based in New Orleans, Obatala develops and manufactures biomaterials, stem cells, media and advanced tissue models to support preclinical medical research. The company’s mission supports America’s ongoing efforts to increase its biomanufacturing and research capacity.

• Obatala’s new operation, located at Blue Sky Labs in Charleston, will facilitate partnership development, translational research, product development and future scale-up activities tied to its human-derived biomaterials and microphysiological model technologies.
• Operations are already online.
• Individuals interested in joining the Obatala team should contact the company (careers@obatalasciences.com).

“Obatala Sciences was founded to change the way new therapies are discovered, tested and translated for patients. Expanding into Charleston County through our partnership with MUSC and Blue Sky Labs gives us access to an extraordinary innovation ecosystem and creates a meaningful bridge between our New Orleans headquarters and South Carolina’s growing life sciences community. Just as importantly, this partnership helps answer a national call to scale domestic advanced biomanufacturing capacity for high-value biotechnology products that support FDA New Approach Methodologies goals. We are excited to collaborate with partners who share our commitment to advancing human-relevant research, strengthening U.S.-based biotechnology infrastructure and creating new opportunities for scientific and economic impact across the Southeast.”
-Obatala Sciences Co-founder, President and CEO Dr. Trivia Frazier PhD, MBA

“We are proud to welcome Obatala to South Carolina. As our state continues to strengthen its position as a leader in manufacturing and technology, we are pleased to see the company bring 46 new jobs to Charleston County.”
-Gov. Henry McMaster

“Obatala’s investment in the Palmetto State will support South Carolina’s ongoing growth in the life sciences sector. We welcome the company to the Lowcountry and look forward to its growth in our state.”
-Secretary of Commerce Harry M. Lightsey III

“Congratulations to Obatala Sciences on expanding its presence to Charleston County. This investment adds meaningful momentum to the region’s growing life sciences sector and strengthens our progress toward a thriving environment that delivers both economic opportunity and improved health outcomes for our community.”
-Charleston County Council Chairman Joe Boykin

“Obatala Sciences’ investment is a great example of the innovation taking place within Charleston’s growing life sciences ecosystem. Their plans at Blue Sky Labs and partnership with MUSC demonstrate the value of having world-class research, clinical expertise and entrepreneurial resources working together in our region. We are proud to welcome this next phase of Obatala Sciences’ growth in Charleston County and look forward to their continued success.”
-Charleston Regional Development Alliance Board Chairman Will Russell

Clemson Rural Health is delivering a new diabetes management program in Orangeburg, South Carolina, and surrounding counties.

Type 2 diabetes disproportionately affects adults in rural South Carolina, where food insecurity, limited healthcare access and barriers to care affect health outcomes. In Orangeburg, Bamberg, Barnwell and Calhoun counties, adults experience elevated rates of diabetes, prediabetes, obesity and hypertension, along with limited access to primary care and low health literacy.

The new ManageTogether CONNECTED (Community Outreach and iNtegrated Nutrition, Education and Coordinated Treatment for Expanded Diabetes management) program builds upon the original ManageTogether program’s success in providing adults with the necessary tools to manage and prevent type 2 diabetes across the region – ultimately, transforming health outcomes in rural communities.

The program incorporates recruitment and engagement strategies to improve participation, strengthen diabetes self-management and reduce complications across underserved rural communities, including the use of a “high touch” community health worker model. Working with a multidisciplinary team, the community health worker will serve as the primary community presence and patient contact, bridging gaps between clinical intervention, social determinants of health and individual needs. Through these efforts, the program is expected to recruit 200 patients and generate approximately 15,830 direct patient interactions with a nurse practitioner, registered dietitian, registered nurse and community health worker over the three-year grant period.

This comprehensive model will utilize continuous glucose monitors, remote patient monitoring, produce prescription boxes, medical nutrition therapy, clinical coordination and diabetes self-management education to empower participants to control their blood sugar and reduce their risk for diabetes-related complications.

The original ManageTogether program was created after local leaders reported that this region has the highest rate of diabetes-related amputations in South Carolina. After its first three years of funding, 70% of its 493 participants experienced a clinically significant decrease in A1c levels. Fourth-year reporting and final findings will be published later this year.

“The results from ManageTogether showed us that intensive, personalized support works,” said Caitlin Moore, DNP, Clemson Rural Health’s associate director for clinical operations and principal investigator on the project. “CONNECTED allows us to pair evidence-based interventions with the kind of hands-on coordination that rural patients often cannot access anywhere else.”

ManageTogether CONNECTED is funded by the BlueCross® BlueShield® of South Carolina Foundation, an independent licensee of the Blue Cross Blue Shield Association, to support the goals of Diabetes Free S.C.

About Clemson Rural Health

Clemson Rural Health is the organizing framework for Clemson’s rural health service delivery and prevention efforts statewide – with locations including the Clemson Health Clinic at Walhalla, Clemson Health Clinic at Orangeburg, Clemson Community Primary Care – home of the Joseph F. Sullivan Center, Clemson Rural Health Support Office at Abbeville, and a fleet of Clemson Rural Health mobile health units. Our vision is to transform health outcomes in rural and underserved communities through reducing premature mortality, decreasing preventable hospitalizations, and improving overall quality of life in the regions we serve.

Clemson Rural Health is a part of the College of Behavioral, Social and Health Sciences, a 21st-century land-grant college joining together a unique combination of schools and departments: Communication, Nursing, Parks, Recreation and Tourism Management, Political Science, Psychology, Public Health Sciences and Sociology, Anthropology and Criminal Justice. These areas have distinctive characteristics and missions – all joined together by a common thread of service to people and communities. For more information, visit ClemsonRuralHealth.org.

New mobile unit will bring clinical and supportive services directly to communities across seven counties

Roper St. Francis Healthcare leaders, community partners and local officials gathered Thursday, Oct. 1, to celebrate the launch of Mobile Care for You, a new mobile unit designed to expand access to clinical and supportive services for communities across the Lowcountry.

Operated by the Roper St. Francis Health Services Center, Mobile Care for You will serve residents across seven counties: Charleston, Berkeley, Dorchester, Williamsburg, Colleton, Horry and Georgetown. The unit will help bring care closer to people who may face transportation, distance and other barriers to accessing healthcare services.

The nearly 40-foot mobile unit features two exam rooms, including one designed for both medical and dental care, as well as a patient waiting and intake area, lab space and wheelchair lift. Mobile Care for You will provide a range of services, including:

• Primary and preventive care
• Health screenings
• Vaccinations
• HIV prevention
• HIV Care
• Testing and treatment linkage
• STI testing and treatment
• PrEP education and navigation
• Care coordination
• Health education
• Preventive dental services

“Mobile Care for You is another way we are advancing our 2030 Strategic Plan and optimizing our footprint to expand access to quality care,” said Joseph DeLeon, President & CEO of Roper St. Francis Healthcare. “Our commitment to the Lowcountry extends beyond the walls of our hospitals and medical offices. By bringing care directly into communities, we can help remove barriers and connect more people with the services and resources they need to live healthier lives.”

Mobile Care for You was developed in response to identified gaps in access to care throughout the region, particularly in rural communities where residents may have to travel greater distances to receive services. The unit gives the Roper St. Francis Health Services Center greater flexibility to take clinical care and resources directly into those communities.

“We recognized that for many people in the communities we serve, the greatest barrier to healthcare is not a lack of desire to receive care—it is access,” said Dr. Tawana Philpott Brown, Program Director of the Roper St. Francis Health Services Center. “Transportation, distance, and limited healthcare resources can make it difficult for individuals to receive the preventive and ongoing care they need. Our mobile health unit allows us to shift the narrative by bringing high-quality, compassionate care directly into communities across our seven-county service area. This is about meeting people where they are, removing barriers, and ensuring that where someone lives does not determine their ability to achieve their best health.”

Mobile Care for You will work alongside Roper St. Francis Healthcare’s existing Mobile Health Unit, which provides health screenings, education and resource connections at community events across the Tri-County Area. The new unit expands that mobile outreach with additional clinical and supportive services and a broader seven-county reach.

As a recipient of federal Ryan White HIV/AIDS Program Part C funding, the Roper St. Francis Health Services Center is eligible to participate in the federal 340B Drug Pricing Program. Savings generated through the Center’s participation in 340B were reinvested to help make Mobile Care for You possible—extending healthcare beyond traditional clinic walls and expanding access to services throughout the communities we serve. The program also relies on partnerships across Roper St. Francis Healthcare and with community organizations to connect residents with needed services and ongoing care. One of those collaborations is an existing partnership with MUSC that will expand access to preventive dental services through the unit.

The partnership between the Roper St. Francis Health Services program and the James B. Edwards College of Dental Medicine at MUSC has resulted in more patients living with HIV and AIDS getting their dental care needs met, said Dr. Amy Martin, Senior Associate Dean at MUSC. It is also strengthening our state’s dental workforce through a clinical rotation in the Roper St. Francis Healthcare program where our students gain knowledge and skill in dentistry for patients living with HIV and AIDS, she said.

“The impact for the state is a dental workforce with greater efficacy in meeting the oral health needs of this special population,” Dr. Martin said. “Building upon the success of this partnership, the Roper St. Francis Health Services Center and MUSC are expanding their footprint into rural communities to increase access to essential health services, including dental care. As our reach grows, so does our vision for oral health access — extending dental services beyond individuals living with HIV to serve people throughout the communities we reach who may otherwise experience barriers to receiving care. Through expanded community partnerships, we are working to bring high-quality, compassionate dental care closer to where people live, particularly in rural and underserved areas.”

About Roper St. Francis Healthcare    

As a not-for-profit healthcare system, Roper St. Francis Healthcare chooses purpose over profits by putting extra money back into the system to help meet the health needs of the Charleston community. The healthcare system features four flagship hospitals: Roper Hospital, Bon Secours St. Francis Hospital, Mount Pleasant Hospital and Berkeley Hospital. In an emergency, the healthcare system offers six strategically placed emergency departments. With nearly 7,000 teammates, Roper St. Francis Healthcare is the Lowcountry’s largest private employer with more than 1,000 doctors representing almost every medical specialty, and it has earned status as a Great Place to Work. The system has nearly 700 beds and about 120 facilities and services across four counties. Learn more: rsfh.com.   

• Broadens GE HealthCare’s footprint in the U.S. radiopharmaceutical industry, drives patient access to F18 labeled Positron Emission Tomography (PET) radiopharmaceuticals and enhances exposure to new high-growth areas
• Pharmaceutical Diagnostics (PDx) continues to partner with other established Contract Manufacturing Organizations (CMOs) to drive and expand patient access to its radiopharmaceutical portfolio, while SOFIE Biosciences continues to supply PET products from other leading radiopharmaceutical providers
• Provides U.S. rights to FAPI-74, a Phase III pipeline PET radiotracer with pan-cancer imaging potential, aiming to be among the first-to-launch in a large and fast-growing market¹

Chicago, IL — October 2026 — GE HealthCare (Nasdaq: GEHC) announced a definitive agreement to acquire SOFIE Biosciences, a leading U.S.-based CMO for PET radiopharmaceuticals, from Trilantic North America, for a purchase price of $945 million paid in cash. The transaction is expected to close in the first half of 2027, subject to closing conditions, including regulatory approvals, at which time SOFIE Biosciences will become part of GE HealthCare’s PDx segment.

The acquisition of SOFIE Biosciences establishes a footprint for GE HealthCare in the time-critical ‘final mile’ of U.S. PET radiopharmaceutical supply, while also enabling PDx to participate in other high growth areas outside its own product portfolio. With a U.S. network of 15 CMO sites operating 21 cyclotrons, and a theranostics-focused Contract Development and Manufacturing Organization (CDMO) site, this acquisition broadens GE HealthCare’s footprint in the U.S. radiopharmaceutical industry, while driving reliable patient access to novel radiopharmaceuticals. It also further enables GE HealthCare’s ability to provide solutions along every step of the theranostics pathway, from cyclotrons to imaging technology, digital workflow tools and radiotherapeutics infrastructure.

“The PET radiopharmaceutical market is expanding rapidly with the introduction of innovative radiotracers and advances in precision care, including the growing adoption of targeted therapies. As part of GE HealthCare, SOFIE Biosciences is expected to grow in the low double digits, and enables us to participate across the radiopharmaceutical value stream, meeting customer demand through a mix of GE HealthCare owned and partner facilities. SOFIE Biosciences has a highly skilled team with deep expertise serving U.S. customers, including manufacturing our Flyrcado™ (flurpiridaz F18 injection) product,” said Kevin O’Neill, President & CEO of the PDx segment at GE HealthCare. “We will leverage our scale and expertise in radiopharmaceutical manufacturing across the U.S., Europe and Japan to further invest in and grow SOFIE Biosciences, helping improve patient access, strengthen reliability of supply, and support the next generation of precision care products.”

PET radiopharmaceuticals are used in precision medicine to visualize metabolic and molecular activity and, increasingly, to deliver targeted therapies across a range of disease areas. F18 labeled PET radiopharmaceuticals have a 110-minute half-life, with PET CMOs playing a crucial role in enabling timely and reliable patient access, both to existing and pipeline products. Industry-wide, the radiopharmaceutical pipeline is growing rapidly, with approximately 20 PET radiotracers and over 30 radiotherapeutics currently under development.² These include SOFIE Biosciences’ Phase III F18 Fibroblast Activation Protein Inhibitor (FAPI) asset, FAPI-74, for which GE HealthCare already holds outside-of-U.S. rights. FAPI has the potential to further expand an already fast-growing global PET imaging market, and is showing strong potential for diagnostic and theranostic use across a range of oncologic and non-oncologic indications. 

GE HealthCare will continue to drive and expand access to its existing proprietary F18 radiopharmaceutical products, while advancing its pipeline of new products, both through SOFIE Biosciences, and PDx’s other established CMO partners across the U.S. 

Serving SOFIE Biosciences’ Customers

Following the transaction close, SOFIE Biosciences will continue to operate as an independent manufacturing partner to its customers, supplying its existing product portfolio, including products from other leading radiopharmaceutical providers.

Patrick Phelps, SOFIE Biosciences co-founder, President & CEO, said, “As demand continues to increase for F18 products, and pipelines for new diagnostics and therapeutics continue to expand, joining GE HealthCare marks an exciting step in our journey as a leading U.S. CMO. With Trilantic North America’s support, we have significantly expanded our capabilities and scale, and we share GE HealthCare’s ambition to improve patient outcomes by delivering on the promise of radiopharmaceuticals as we look ahead to our next phase of growth.”

Ted Rosenwasser, Partner, Trilantic North America, said, “We are incredibly proud of what Patrick and the SOFIE Biosciences team have accomplished during our partnership. SOFIE Biosciences has grown significantly, investing in its network and manufacturing capabilities to help meet growing demand and enable increased and reliable patient access to critical products. GE HealthCare’s legacy and global expertise make it a natural partner to support SOFIE Biosciences’ continued growth and help expand access for U.S. patients to novel diagnostic and therapeutic radiopharmaceuticals.”

GE HealthCare’s Pharmaceutical Diagnostics segment is a global leader in imaging agents used to support 140 million procedures in 2025, equivalent to four patient procedures every second. For more than 40 years, GE HealthCare’s imaging agents have been routinely used across care pathways to support diagnosis. 

Financial Benefits 

GE HealthCare estimates that the transaction will be accretive to revenue growth, Adjusted earnings before interest and taxes margin* and Adjusted earnings per share* in the first full year of ownership.

Advisors

For GE HealthCare, BofA Securities, Consello Financial LLC and Solomon Partners Securities LLC served as financial advisors. 

Forward-Looking Statements

This release contains forward-looking statements. These forward-looking statements might be identified by words, and variations of words, such as “will,” “expect,” “may,” “would,” “could,” “plan,” “believe,” “anticipate,” “intend,” “estimate,” “potential,” “position,” and similar expressions. These forward-looking statements may include, but are not limited to, statements about the transaction, the completion and expected results of the transaction including the financial performance of the business, industry positioning, and GE HealthCare Technologies Inc.’s (“the Company’s”) business, products, growth opportunities, and strategy. These forward-looking statements involve risks and uncertainties, many of which are beyond the control of the Company. Factors that could cause the Company’s actual results to differ materially from those described in its forward-looking statements include, but are not limited to, the conditions to the completion of the transaction may not be satisfied; closing of the transaction may not occur or may be delayed; the Company may be unable to achieve the anticipated benefits of the transaction; operating costs and business disruptions (including, without limitation, difficulties in maintaining relationships with employees, customers, and suppliers) may be greater than expected; the Company may assume unexpected risks and liabilities; and completing the transaction may distract the Company’s management from other important matters. Other factors that may cause such a difference also include those discussed in the “Risk Factors” section of the Company’s Annual Report on Form 10-K filed with the U.S. Securities and Exchange Commission and any updates or amendments it makes in future filings. There may be other factors not presently known to the Company or which it currently considers to be immaterial that could cause the Company’s actual results to differ materially from those projected in any forward-looking statements the Company makes. The Company does not undertake any obligation to update or revise its forward-looking statements except as required by applicable law or regulation.

References:

1. https://researchintelo.com/report/fapi-pet-imaging-market 

2. MEDraysintell Report, 2025 Edition 

About SOFIE Biosciences

SOFIE Biosciences’ mission is to improve patient outcomes by developing and delivering molecular diagnostics and therapeutics (Theranostics). With a robust radiopharmaceutical production and distribution network, mature contract manufacturing services, and high-value Theranostic intellectual property, SOFIE Biosciences is delivering on the promise of radiopharmaceuticals. For more information, please visit www.sofie.com or info@sofie.com. 

About Trilantic North America

Trilantic Capital Management L.P. (“Trilantic North America”) is a growth-focused middle market private equity firm focused on control and significant minority investments in North America. Trilantic North America’s primary investment focus is in the business and consumer services sectors. Since inception, Trilantic North America has managed seven private equity fund families, representing $11.6B in raised capital commitments. For more information, visit www.trilanticnorthamerica.com.

*Non-GAAP financial measure; see our earnings release dated July 29, 2026 for definitions.

About GE HealthCare Technologies Inc.

GE HealthCare is a leading global healthcare solutions provider of advanced medical technology, pharmaceutical diagnostics, and AI, cloud and software solutions that help clinicians tackle the world’s most complex diseases. Serving patients and providers for 130 years, GE HealthCare is delivering bold innovations designed for the next era of medicine across its Advanced Imaging Solutions, Pharmaceutical Diagnostics, and Patient Care Solutions segments to help clinicians deliver more personalized, precise patient care. We are a $20.6 billion business with approximately 54,000 colleagues working to create a world where healthcare has no limits.

GE HealthCare is proud to be among 2026 Fortune World’s Most Admired Companies™.

Follow us on LinkedIn, Facebook, Instagram, or visit our website for our latest news and perspectives. 

Download Article

Media Contacts

GE HealthCare Media Contact

Emmy Elguizaoui

+1-978-243-7503

emmy.elguizaoui@gehealthcare.com

GE HealthCare Investor Relations Contact 

Carolynne Borders

+1-631-662-4317

carolynne.borders@gehealthcare.com

SOFIE Biosciences / Trilantic North America Contact

Prosek Partners 

Pro-trilantic@prosek.com

Agreement supports significant investments in U.S. manufacturing, strengthens healthcare resilience and increases domestic production of essential medical consumables used in approximately 90% of U.S. hospital visits   

FRANKLIN LAKES, N.J., Oct. 6, 2026 /PRNewswire/ — BD (Becton, Dickinson and Company) (NYSE: BDX), one of the world’s leading medical technology companies and the nation’s largest manufacturer of essential medical consumables, today announced a landmark partnership with the U.S. Government to expand domestic manufacturing and strengthen the resilience of supply chains for essential medical consumables relied on by clinicians and patients every day.  

Recognizing BD’s critical role in America’s healthcare infrastructure, the agreement supports significant investments in U.S. manufacturing, innovation and end-to-end production capabilities. The partnership aligns with the Trump administration’s efforts to expand domestic manufacturing capacity and ensure a resilient supply chain for products critical to patient care and healthcare preparedness. 

“This agreement reflects a shared commitment between the U.S. Government and BD to strengthening America’s healthcare infrastructure, expanding U.S. manufacturing capacity and supporting reliable access to essential medical technologies, ultimately building a more resilient healthcare system for the future,” said Tom Polen, chairman, CEO and president of BD. “The administration recognizes the importance of investing in a stronger, more secure healthcare supply chain, and BD is uniquely positioned to help bring that vision to life through our scale, innovation expertise and longstanding U.S. manufacturing footprint. 

For nearly 130 years, BD has partnered with health systems and governments in the U.S. and around the world to meet critical healthcare challenges. We are proud to build on that legacy through significant investment in U.S. manufacturing and innovation, while continuing to advance healthcare and serve patients, providers and communities around the world who depend on us.”   

Through this partnership, BD intends to:  

• Invest $19 billion in the U.S. over several years, including capital, operational and supply chain investments.
• Direct $3 billion of the overall investment toward U.S. manufacturing expansion focused on strategic production sites across the country.
• Expand end-to-end U.S. production by approximately 5 billion essential medical consumables annually, raising BD’s share of domestically supplied essential medical consumables to roughly 80 percent.
• Manufacture 100 percent of BD needles used in America domestically using American-made steel.

The agreement also provides relief from future tariffs imposed under Section 232 on covered BD products and inputs, subject to the final scope and implementation of any future Section 232 actions and BD’s achievement of agreed milestones. This provides greater long-term certainty for manufacturing and supply chain planning as BD advances investments in U.S. production, innovation and healthcare infrastructure. Because the final tariff rates, product scope and effective timing have not yet been determined, BD is not currently quantifying the financial impact of the agreement. The company expects to provide additional information when the Section 232 tariffs are finalized.   

BD’s U.S. manufacturing network is deeply rooted in communities across the country, including Columbus and Broken Bow, NE; Canaan, CT; Añasco, PR; Sandy, UT; El Paso, TX; Covington, GA; and Sumter, SC. For generations, BD has helped meet critical healthcare needs through innovation, manufacturing excellence and the reliable supply of essential medical technologies. From developing the first disposable syringe that helped advance the fight against polio to delivering more than two billion additional devices during the recent pandemic, BD has worked alongside healthcare providers and governments to respond to evolving patient and public health needs. 

Collectively, these commitments will help establish one of the world’s most resilient essential medical consumables manufacturing bases and strengthen America’s healthcare resilience for future generations. The investments also reinforce BD’s broader commitment to advancing innovation and strengthening healthcare systems around the world. 

About BD  
BD is one of the world’s largest pure-play medical technology companies with a Purpose of advancing the world of health™ by driving innovation across medical essentials, connected care, biopharma systems and interventional. The company supports those on the frontlines of healthcare by developing transformative technologies, services and solutions that optimize clinical operations and improve care for patients. Operating across the globe, with more than 60,000 employees, BD delivers billions of products annually that have a positive impact on global healthcare. By working in close collaboration with customers, BD can help enhance outcomes, lower costs, increase clinical efficiency, improve safety and expand access to healthcare. For more information on BD, please visit bd.com or connect with us on LinkedIn at www.linkedin.com/company/bd1/, X @BDandCo or Instagram @becton_dickinson.  

Cautionary Statement Regarding Forward-Looking Statements
This press release contains forward-looking statements (as defined under federal securities laws) regarding, among other things, BD’s agreement with the U.S. government and each party’s commitments therein. All statements that are not statements of historical facts are, or may be deemed to be, forward-looking statements. Such forward-looking statements are based on current expectations and projections of BD’s management about our future financial results, goals, plans and objectives and involve inherent risks, assumptions and uncertainties, including internal or external factors that could delay, divert or change any of them in the next several years, that are difficult to predict, may be beyond our control and could cause our future financial results, goals, plans and objectives to differ materially from those expressed in, or implied by, the statements. Forward-looking statements in this press release should be evaluated together with the many risks and uncertainties that affect BD’s business and market, particularly those identified in the cautionary statement and risk factors discussed in BD’s latest Annual Report on Form 10-K and other filings with the Securities and Exchange Commission. The forward-looking statements included in this press release are made only as of the date of this press release and except as otherwise required by applicable law, BD undertakes no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events, changed circumstances or otherwise. 

SOURCE BD (Becton, Dickinson and Company)